Insider Selling: Privia Health Group, Inc. (NASDAQ:PRVA) CFO Sells 3,322 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 3,322 shares of the firm’s stock in a transaction on Monday, May 12th. The stock was sold at an average price of $24.99, for a total value of $83,016.78. Following the transaction, the chief financial officer now owns 172,909 shares in the company, valued at $4,320,995.91. The trade was a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

David Mountcastle also recently made the following trade(s):

• On Wednesday, April 30th, David Mountcastle sold 3,445 shares of Privia Health Group stock. The stock was sold at an average price of $23.33, for a total value of $80,371.85.
• On Wednesday, April 2nd, David Mountcastle sold 5,630 shares of Privia Health Group stock. The stock was sold at an average price of $22.38, for a total value of $125,999.40.

Privia Health Group Price Performance

Shares of Privia Health Group stock opened at $24.30 on Thursday. The firm has a market cap of $2.95 billion, a P/E ratio of 243.02, a P/E/G ratio of 3.47 and a beta of 0.87. The business has a 50-day moving average price of $23.32 and a 200 day moving average price of $22.42. Privia Health Group, Inc. has a fifty-two week low of $15.92 and a fifty-two week high of $26.09.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PRVA. Rhumbline Advisers grew its holdings in Privia Health Group by 1.3% in the 4th quarter. Rhumbline Advisers now owns 287,200 shares of the company’s stock worth $5,615,000 after buying an additional 3,658 shares in the last quarter. Barclays PLC increased its holdings in shares of Privia Health Group by 240.3% during the third quarter. Barclays PLC now owns 224,018 shares of the company’s stock valued at $4,079,000 after purchasing an additional 158,188 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Privia Health Group by 8.4% during the third quarter. JPMorgan Chase & Co. now owns 188,384 shares of the company’s stock valued at $3,430,000 after purchasing an additional 14,641 shares in the last quarter. Choreo LLC lifted its holdings in Privia Health Group by 8.7% in the fourth quarter. Choreo LLC now owns 21,841 shares of the company’s stock worth $425,000 after purchasing an additional 1,752 shares during the period. Finally, PNC Financial Services Group Inc. grew its position in Privia Health Group by 8.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,169 shares of the company’s stock valued at $140,000 after buying an additional 533 shares in the last quarter. 94.48% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PRVA shares. JMP Securities restated a “market outperform” rating and issued a $29.00 target price on shares of Privia Health Group in a research note on Monday, April 28th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price objective on shares of Privia Health Group in a research report on Thursday, April 10th. Robert W. Baird increased their target price on Privia Health Group from $24.00 to $26.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 15th. Canaccord Genuity Group boosted their price objective on Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Finally, Piper Sandler raised their price objective on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $27.38.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.